Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

The goal of this study is to evaluate the safety and effectiveness of adjuvant chemoradiation therapy in high-risk breast cancer patients who had received neoadjuvant chemotherapy before their lumpectomy and/or mastectomy and were found to have residual disease. As well as examine the effects of this treatment combination on the immune system.

Trial Details

NCT ID
NCT05288777
Phase
PHASE2 / PHASE3
Sponsor
University of Virginia
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • T-DM1
  • Capecitabine
  • External Beam Radiation Therapy 0
  • External Beam Radiation Therapy 1
Locations (sample)
  • Charlottesville, Virginia, United States|38.02931,-78.47668

Key Eligibility Criteria

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged 18 or older
  • Diagnosis of stage I-IIIB breast cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →